Highlights
A collection of news and information related to AstraZeneca Plc published by this site and its partners.
Displaying items 1-12 of 88
» View courant.com items only
1
2
3
4
5
6
7
8
•
Next >
-
Stimulus fears haunt share markets, dollar recovers
ReutersNEW YORK (Reuters) - Global equity markets slipped on Friday over worries the U.S. Federal Reserve may curb a stimulus program that has lifted stocks, while the dollar recovered against the euro after better-than-expected U.S. durable goods data for...Tags: Moody's Corporation, Heavy Engineering, Market and Exchange, BB&T Corp., Lebanon
-
U.S. lawmaker would give FDA more oversight of drug compounding
ReutersBy Toni Clarke WASHINGTON, May 23 (Reuters) - Representative Edward Markey, a Democrat from Massachusetts, on Thursday became the latest lawmaker to propose legislation that would give the U.S. Food and Drug Administration greater regulatory authority...Tags: Food and Drug Administration, Crime, Law and Justice, Science and Technology, Meningitis, Biotechnology Industry
-
Lawmaker would give FDA more oversight of drug compounding
ReutersWASHINGTON (Reuters) - Representative Edward Markey, a Democrat from Massachusetts, on Thursday became the latest lawmaker to propose legislation that would give the U.S. Food and Drug Administration greater regulatory authority over drug compounding. U....Tags: Food and Drug Administration, Science and Technology, Crime, Law and Justice, Meningitis, Biotechnology Industry
-
Immune system cancer drugs tipped to be a $35 bln market
Reuters* Potential sales of $35 bln a year over next 10 years - Citigroup * Immunotherapy may be used in up to 60 percent of cancers * Bristol-Myers Squibb and Roche both upgraded to "buy" By Ben Hirschler LONDON, May 22 (Reuters) - A new wave of medicines...Tags: Vaccines, Weather Reports, Citigroup Incorporated, Merck & Company Incorporated, Roche Holding AG
-
Immune system cancer drugs tipped to be a $35 billion market
ReutersLONDON (Reuters) - A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year. That bullish sales forecast by analysts at U.S. bank...Tags: Vaccines, Weather Reports, Citigroup Incorporated, Merck & Company Incorporated, Roche Holding AG
-
Inmunoterapia contra el cáncer podrÃa ser un mercado de 35.000 mln dlrs anuales
ReutersPor Ben Hirschler LONDRES, 22 may (Reuters) - Una nueva ola de medicinas que emplea el poder del sistema inmunológico para luchar contra el cáncer podrÃa convertirse en el mayor grupo de medicamentos de la historia, con ventas potenciales de 35.000...Tags: GlaxoSmithKline PLC, Citigroup Incorporated, Novartis AG, Merck & Company Incorporated, Bristol Myers Squibb Company
-
AstraZeneca closes in on site for new home in Cambridge
Reuters* Drugmaker eyes Cambridge Biomedical Campus - sources * Relocation centrepiece of new CEO's restructuring plan * New research centre and corporate HQ to cost some $500 mln By Ben Hirschler and Tom Bill LONDON, May 20 (Reuters) - AstraZeneca is...Tags: University of Cambridge, England, Entertainment Events, Biology, Elizabeth II
-
Mexicana Genomma Lab distribuirá marca de antiácidos Losec
ReutersMONTERREY, 20 mayo (Reuters) - La farmacéutica mexicana Genomma Lab dijo el lunes que firmó un contrato de licencia para el uso de la marca de medicamentos de libre venta Losec, que le permitirá distribuir el popular antiácido por 99 años. Genomma... -
Cubist bid almost $1 bln for Optimer before sale process-sources
ReutersBy Jessica Toonkel NEW YORK, May 15 (Reuters) - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people...Tags: Thomson Corporation, Cubist Pharmaceuticals Incorporated, Diarrhea, Japan
-
A taste for defensives sours prospects for European stocks
Reuters* Defensive stocks unusually leading Europe stock rally * Healthcare price/earnings ratios at five-year highs * Fund managers still favour defensives -BofA ML survey By Tricia Wright LONDON, May 14 (Reuters) - Defensive stocks such as healthcare...Tags: Pharmaceuticals, Thomson Corporation, Mutual Funds, Finance, Earnings Forecasts
-
RPT-ANALYSIS-Drugmakers face more scrutiny of discordant U.S. prices
Reuters(Repeats to widen readership) By Deena Beasley LOS ANGELES, May 10 (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc...Tags: Barack Obama, Patient Protection and Affordable Care Act, Health Insurance, Deloitte Touche Tohmatsu Ltd., National Government
-
U.S. spending on medicines fell for first time in 2012
Reuters(Reuters) - Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday. Overall U.S....Tags: Flu, Patient Protection and Affordable Care Act, Patents, Copyrights and Trademarks, Plavix (drug), Statins (drugs)
May 24, 2013
|Story| Reuters
May 23, 2013
|Story| Reuters
May 23, 2013
|Story| Reuters
May 22, 2013
|Story| Reuters
May 22, 2013
|Story| Reuters
May 22, 2013
|Story| Reuters
May 20, 2013
|Story| Reuters
May 20, 2013
|Story| Reuters
May 15, 2013
|Story| Reuters
May 14, 2013
|Story| Reuters
May 10, 2013
|Story| Reuters
May 8, 2013
|Story| Reuters
Original site for AstraZeneca Plc topic gallery.
